GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tarsus Pharmaceuticals
Shares of Tarsus, a biopharmaceutical company, soared on the success of its drug for the treatment of demodectic blepharitis. The price chart tells the story of the commercialization of the first and only approved treatment for this common eyelid disorder.
Share prices of companies in the market segment - Pharma infections
Tarsus is a biopharmaceutical company specializing in the treatment of eye diseases. Its business consists of a single segment, driven by its flagship drug, Xdemvy. We classify it as part of the Pharmaceutical Infections sector, and the chart below reflects the dynamics of the entire biotech industry operating in ophthalmology.
Broad Market Index - GURU.Markets
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of eye diseases. Its focus on this niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Tarsus compares to it.
Change in the price of a company, segment, and market as a whole per day
TARS - Daily change in the company's share price Tarsus Pharmaceuticals
Shares of Tarsus Pharmaceuticals, a biopharmaceutical company, are highly volatile. Change_co measures market reaction to the commercial success of its first drug and news of new developments. This metric is an important component of the formulas on System.GURU.Markets that evaluate young pharmaceutical companies.
Daily change in the price of a set of shares in a market segment - Pharma infections
Tarsus Pharmaceuticals, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to TARS, which focuses on eye care, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Tarsus Pharmaceuticals is a biopharmaceutical company specializing in the treatment of ophthalmological diseases. Ophthalmology is a highly specialized and competitive field. The chart below shows volatility in this sector, allowing you to assess how Tarsus shares react to industry news.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tarsus Pharmaceuticals
Tarsus is a biopharmaceutical company specializing in infectious diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Pharma infections
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of eye diseases. Its success depends on the commercialization of its first approved drug. This chart shows how the market perceives the potential of its drugs and how it moves from development to commercialization in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tarsus Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tarsus Pharmaceuticals
Tarsus, a biopharmaceutical company focused on treating eye diseases, has monthly fluctuations reflecting the commercial success of its first approved drug and news about the development of other products.
Monthly dynamics of market capitalization of the market segment - Pharma infections
Specialty pharmaceuticals, particularly in ophthalmology, are a market where innovation and successful clinical trials are crucial. The dynamics of this segment, shown in the chart, reflect investors' faith in new treatments. This is the context in which companies like Tarsus Pharmaceuticals are bringing their developments to market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tarsus Pharmaceuticals is a biotech company focused on ophthalmology. Its shares are driven by news of drug approvals and commercial launches. Their performance is largely independent of overall market trends, driven instead by success in their niche.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company whose first product is designed to treat demodectic blepharitis (eyelid inflammation). Its weekly stock price is driven by sales reports for this drug, insurance coverage news, and progress in developing other medications.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Tarsus, as a commercial biopharmaceutical company with a single key product, can move differently than diversified giants. The successful launch and sales growth of its drug is a unique driver. The chart allows for comparison with the broader pharmaceutical sector and shows how the market values a growth story focused on a single drug.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tarsus Pharmaceuticals is a biotech company whose first drug targets eyelash mites. It's a unique niche. The chart will show how its stock, driven by sales news, has a life of its own, independent of market trends.
Market capitalization of the company, segment and market as a whole
TARS - Market capitalization of the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals' market capitalization chart represents the biotech company's successful launch of its first product. The growth in the chart reflects the commercial success of its drug for the treatment of demodectic blepharitis. Investors are now assessing its ability to develop other drugs in its portfolio and become a diversified pharmaceutical company.
TARS - Share of the company's market capitalization Tarsus Pharmaceuticals within the market segment - Pharma infections
Tarsus Pharmaceuticals is targeting the ophthalmology market with its innovative drug for the treatment of demodectic blepharitis, a common eyelid disorder. Its market cap is based on the potential of being the first and only approved treatment for this condition.
Market capitalization of the market segment - Pharma infections
Here's a chart showing the market capitalization of the ophthalmic pharmaceuticals sector. Tarsus Pharmaceuticals is an innovator that created the first approved drug for demodectic blepharitis, a common eyelid disorder. The success of companies like Tarsus demonstrates how solving a previously ignored problem can create an entirely new multi-million dollar market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Tarsus Pharmaceuticals develops drugs to treat common eye diseases. Its market capitalization is based on the potential to bring therapies to market for previously neglected conditions. The chart below shows the weighting of biotech companies targeting mass but complex markets.
Book value capitalization of the company, segment and market as a whole
TARS - Book value capitalization of the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals' foundation is its intellectual property, XDEMVY, the first and only approved treatment for demodectic blepharitis. This timeline tells the story of a biotech company's transformation from development to a commercial enterprise, where the success of a single product begins to build a solid asset base.
TARS - Share of the company's book capitalization Tarsus Pharmaceuticals within the market segment - Pharma infections
Tarsus Pharmaceuticals develops drugs for common but neglected diseases. The chart shows its share of actual R&D assets. These are its laboratories where research is conducted to create new drugs aimed at improving the quality of life of millions of people.
Market segment balance sheet capitalization - Pharma infections
Tarsus Pharmaceuticals is a biotech company, which accounts for its low capital intensity. Its value lies in developing a drug for the treatment of demodectic blepharitis, not in its manufacturing capacity. Compared to the pharmaceutical sector, its "light" balance sheet is typical of companies launching their first innovative product.
Book value of all companies included in the broad market index - GURU.Markets
Tarsus Pharmaceuticals' assets are not product lines, but concentrated scientific capital focused on solving previously neglected eye diseases. The company's balance sheet reflects the value of its research and development (R&D) and patents. The chart shows the volume of resources invested in developing new treatments that change patients' lives.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biotech company whose market value is based on the potential of its drugs, not its assets. Investors aren't buying lab equipment, but the potential to commercialize a new treatment. The gap between the market and book valuation on the chart is a measure of the company's hopes for a future blockbuster.
Market to book capitalization ratio in a market segment - Pharma infections
Tarsus Pharmaceuticals develops drugs to treat common but neglected diseases. Its value reflects the potential of its lead product. This chart illustrates how high investor expectations are for the commercialization of this drug compared to the company's modest financial base.
Market to book capitalization ratio for the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its market capitalization is based on the expected commercial success of its drugs, not on the value of its laboratories. This chart demonstrates how much a biotech company's valuation can exceed its book value due to the potential of its developments.
Debts of the company, segment and market as a whole
TARS - Company debts Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Bringing a new drug to market is a long and expensive process. Debt financing is a way for the company to ensure the continuity of clinical trials and prepare for the commercial launch of its flagship product.
Market segment debts - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. After receiving approval for its first product, its financial strategy shifted from R&D to commercialization. This chart shows how the company financed its sales and marketing launch: through revenue generation or by raising debt for scaling.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company commercializing its first product for the treatment of demodectic blepharitis. This chart shows its financial position at the launch stage. Capital is being used to build commercial infrastructure, marketing, and physician training, which are critical to successfully bringing a new drug to market.
Market segment debt to market segment book capitalization - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. The chart shows the overall debt burden in a sector where funding clinical trials is key. It provides an insight into how Tarsus's capital raising strategy compares to companies at the market launch stage.
Debt to book value of all companies in the market
Tarsus Pharmaceuticals, like other biotechs, relies on venture capital funding. The chart shows the overall debt burden for the entire economy. It clearly demonstrates that while mature companies respond to credit cycles, Tarsus's future is determined not by the state of debt markets, but by success in clinical trials.
P/E of the company, segment and market as a whole
P/E - Tarsus Pharmaceuticals
This chart for Tarsus Pharmaceuticals, which focuses on treating eye infections, is an assessment of its commercial potential. Following the approval of its first drug, the price-to-earnings ratio shows how successful investors believe its sales will be. The price-to-earnings ratio reflects the market's reaction to the revenue reports and the company's confidence in its ability to establish itself in the market.
P/E of the market segment - Pharma infections
This chart reflects the average valuation for the biopharmaceutical sector—the benchmark for Tarsus. Comparing the valuation of a company with an approved product to the industry average (including many companies without revenue) helps understand how optimistic the market is about the commercial potential of its first drug and future developments.
P/E of the market as a whole
Tarsus Pharmaceuticals develops drugs to treat common but often overlooked eye diseases, such as demodectic blepharitis. The company's success depends on creating a new market. This graph of investor risk appetite shows how willing they are to invest in companies that aren't just creating new drugs, but changing the standard of care for millions of people.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by Demodex mites. The company's success depends on the commercialization of its first approved drug. This chart shows how analysts project future sales and profitability based on market acceptance of the new treatment.
%20P%2FE%20Tarsus%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tarsus-Pharmaceuticals&v=1772617281474 "Chart of the company's future (projected) P/E Tarsus Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its valuation relative to other players in the sector reflects investor expectations for its commercial launch and future developments. A premium valuation may reflect the belief that its products will become leaders in their niche and standard treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772617281504 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its first commercial product is designed to treat blepharitis caused by Demodex mites. The company's success depends on the rapid adoption of this new drug by doctors and patients. This chart shows the overall market risk appetite, which influences the valuation of young biopharmaceutical companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772617281547 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on the treatment of eye diseases caused by Demodex mites. Its financial performance, as reflected here, is dependent on the successful commercialization of its first approved drug. Market and medical acceptance of this new treatment is key to its growth.
Profit of companies in the market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by mites (Demodectic blepharitis). This chart shows the overall profitability of niche pharmaceutical companies. It helps assess whether drugs for previously neglected conditions can find a market and become commercially successful.
Overall market profit
Tarsus Pharmaceuticals develops drugs to treat often overlooked conditions, such as demodectic blepharitis. The company's success depends on its ability to commercialize its developments and convince doctors and patients of their effectiveness. This is a micro-task, only indirectly affected by the macroeconomic cycles shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its future profitability is directly tied to the commercial success of its first approved drug. This chart reflects analysts' expectations for the speed of adoption by doctors and patients, as well as its potential to become a standard of care in its niche.
%20profit%20of%20the%20company%20Tarsus%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tarsus-Pharmaceuticals&v=1772617281760 "Graph of future (projected) profit of the company Tarsus Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its first commercial product is designed to treat demodicosis blepharitis, a common eyelid inflammation. This chart shows forecasts for the ophthalmology segment. It helps assess how Tarsus can contribute with a new drug to a previously unmet need.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772617281779 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. The overall economic climate, illustrated by this chart, influences investor sentiment. Positive market expectations facilitate raising capital to fund clinical trials and commercialization of new drugs, which is critical for Tarsus.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772617281816 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. With an approved product, the company is beginning to generate revenue. This chart shows how investors view its early sales and potential for further growth in the ophthalmology market.
P/S market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by Demodex mites. This chart shows the average valuation in the infectious diseases sector. It reflects investor expectations for the company, which has launched the first approved drug to treat blepharitis caused by these parasites.
P/S of the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by Demodex mites with an innovative drug. The company's success and revenue depend on the commercialization of its core product. This chart helps investors compare the company's high valuation, based on expectations, with realistic revenue estimates in other sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by Demodex mites. Its future revenue depends on the successful commercialization of its first approved drug. This chart shows how the market perceives the potential sales volume of this innovative product and its potential to become a standard of care.
%20P%2FS%20Tarsus%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tarsus-Pharmaceuticals&v=1772617281969 "The graph of the company's future (projected) P/S Tarsus Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating ectoparasite-related diseases, such as demodectic blepharitis (eyelid inflammation). Its first product targets a huge, untapped market. This chart reflects investor expectations for the commercial success of this niche drug compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772617282024 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
This reflects investors' faith in pharmaceutical innovation. For Tarsus Pharmaceuticals, a company focused on treating eye diseases such as demodectic blepharitis, this reflects the market's appetite for new solutions. Investor optimism helps fund the launch of drugs that address previously unmet patient needs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772617282064 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its first commercial product is designed to treat demodectic blepharitis. This chart shows the sales revenue of this innovative drug. Increased sales will signal the successful introduction of a new standard of treatment for this common eyelid condition.
Sales of companies in the market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company specializing in the treatment of parasitic eye diseases. This chart shows the market size of drugs for the treatment of infectious diseases. Tarsus launched the first approved drug for the treatment of demodectic blepharitis, addressing an unmet medical need and changing standards in ophthalmology.
Overall market sales
Tarsus Pharmaceuticals is a biopharmaceutical company specializing in the treatment of eye infections. Its development depends on successful clinical trials and subsequent market acceptance. The overall economic situation, shown in this chart, affects the availability of capital for research funding and the solvency of the healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating parasitic eye diseases. Its first commercial product targets demodectic blepharitis. This graph reflects analysts' expectations for the speed of adoption of the new drug by physicians and patients, as well as the potential of the company's other ophthalmology developments.
%20sales%20of%20the%20company%20Tarsus%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tarsus-Pharmaceuticals&v=1772617282199 "Schedule of future (projected) sales of the company Tarsus Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by Demodex mites. The forecast reflects expectations for the niche infectious disease pharmaceutical segment. It shows the potential demand analysts see for innovative treatments for common but often overlooked conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772617282226 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing treatments for eye diseases. Its commercial success will depend on the approval and market acceptance of its products. The overall economic environment, reflected in this chart, impacts the ability of patients and healthcare systems to pay, as well as the availability of capital for further research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772617282286 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. This chart shows financial results at the commercialization stage of the first product. Profitability depends on the successful launch of the drug, its acceptance by doctors and patients, and the ability to cover marketing and manufacturing costs with revenue.
Market segment marginality - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing treatments for infectious eye diseases. Currently in the commercialization phase of its first product, its profitability will depend on a successful launch. This chart illustrates the company's current operating structure compared to other companies in the ophthalmology sector.
Market marginality as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases caused by Demodex mites. This overall profitability curve is irrelevant to the company. Tarsus's success and profitability depend on the effectiveness of its drug, its regulatory approval, and its ability to create a new market for the treatment of a previously neglected disease.
Employees in the company, segment and market as a whole
Number of employees in the company Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. The graph shows the team, which has launched its first product and is working on new ones. Headcount growth, particularly in sales and marketing, is a key indicator of successful commercialization.
Share of the company's employees Tarsus Pharmaceuticals within the market segment - Pharma infections
Tarsus Pharmaceuticals develops innovative treatments for eye diseases caused by Demodex mites. The team defines success in this niche. This chart shows the percentage of leading ophthalmologists, parasitologists, and clinicians focused on this problem that the company attracts, reflecting its unique concentration of expertise in solving a specific medical problem.
Number of employees in the market segment - Pharma infections
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company focused on treating diseases caused by ectoparasites. Its first product targets demodectic blepharitis, a common eyelid inflammation. This chart reflects employment in niche pharmaceuticals, showing how developing therapies for previously ignored but common conditions is creating new markets and jobs.
Number of employees in the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Their success depends on scientific breakthroughs and regulatory approvals, not on general economic cycles. They are an example of a knowledge-based industry that creates high-paying jobs for scientists. Such companies form the innovative core of the economy of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. This chart shows how the market values the commercialization of science. Its high market capitalization per employee reflects the success of its first drug and potential for further growth. The market values intellectual property and market share, not personnel.
%20of%20the%20company%20Tarsus%20Pharmaceuticals%20(TARS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tarsus-Pharmaceuticals-TARS&v=1772617282677 "Chart of market capitalization per employee (in thousands of dollars) of the company Tarsus Pharmaceuticals (TARS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Tarsus Pharmaceuticals (TARS) is a biopharmaceutical company whose first product (XDEMVY) is designed to treat demodectic blepharitis (an eyelid inflammation caused by mites). This chart shows the average market capitalization per employee in the sector. It helps assess how the market views the commercial launch of their niche drug and their R&D potential per employee.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772617282694 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. This chart illustrates the average market capitalization per employee, highlighting how the market values the potential for new drug approvals and intellectual property.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772617282778 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals is a biopharmaceutical company focused on eye diseases. Their first product was recently approved. This chart shows the transition from an R&D company (loss per employee) to a commercial one. It reflects how effectively their small team (scientists and now salespeople) generates sales revenue.
%20Chart%20Tarsus%20Pharmaceuticals%20(TARS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tarsus-Pharmaceuticals-TARS&v=1772617282815 "Company Profit Per Employee (in thousands of dollars) Chart Tarsus Pharmaceuticals (TARS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Tarsus (TARS) is an R&D biotech company (an approved drug for eyelash mites). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (biotech) is high. This benchmark reflects a "one-hit wonder": the sector spends millions on R&D, and a single successful "niche" drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772617282826 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company whose first product (a treatment for demodectic blepharitis, an eyelid disorder) recently received approval. This chart is intended to show the turning point: from negative profit per employee (R&D) to positive. It reflects how successfully the marketing and sales team is bringing a new drug to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772617282839 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. This graph shows the path from scientific development to commercial success. It illustrates how bringing a high-demand product to market can dramatically change financial performance, generating high revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tarsus-Pharmaceuticals-TARS&v=1772617282852 "Sales chart per company employee Tarsus Pharmaceuticals (TARS)")
Sales per employee in the market segment - Pharma infections
Tarsus Pharmaceuticals is a commercial biotech company focused on treating eye diseases, specifically demodectic blepharitis. This chart shows the average revenue per employee in the segment. It allows us to assess how productive Tarsus's R&D and commercialization team is in the highly specialized ophthalmology niche compared to its competitors.
Sales per employee for the market as a whole
Tarsus Pharmaceuticals is a biopharmaceutical company that recently received approval and launched its first product for the treatment of an eye disease (Demodectic blepharitis). This chart is becoming critically important. It demonstrates how effectively their newly formed commercial team (sales, marketing) is converting R&D into actual revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals is a biopharmaceutical company whose first drug (for the treatment of demodectic blepharitis, an eyelid disorder) recently hit the market. Its success hinges on how quickly doctors begin prescribing it. This chart shows the percentage of skeptics who doubt the commercial success of the launch or believe the market for this drug is small.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tarsus-Pharmaceuticals-TARS&v=1772617282897 "Short Shares Chart for the Company Tarsus Pharmaceuticals (TARS)")
Shares shorted by market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company whose flagship product targets demodectic blepharitis (an eyelid inflammation caused by mites). It's a niche but widespread market. This chart shows the total short position in the ophthalmology biotech sector. The high figure reflects general investor skepticism about the commercial success of new drugs in this niche.
Shares shorted by the overall market
Tarsus (TARS) is a biotech focused on eye diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially biotechs. This pessimism, visible on the chart, puts pressure on growth stocks like TARS, even if they have an approved drug.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals (TARS) is a biopharmaceutical company focused on treating diseases caused by ectoparasites. Their first commercial product is designed to treat demodectic blepharitis (an eyelid inflammation caused by mites). This chart measures hype. It shows "overbought" (above 70) on news of a successful product launch or "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tarsus-Pharmaceuticals-TARS&v=1772617283238 "RSI 14 indicator chart for the company's stock Tarsus Pharmaceuticals (TARS)")
RSI 14 Market Segment - Pharma infections
Tarsus Pharmaceuticals (TARS) is a biopharmaceutical company focused on treating eyelid diseases, specifically demodectic blepharitis (caused by mites). They have carved out a new niche. This chart tracks the overall sentiment in the Pharma/Infectious Diseases sector. It helps distinguish TARS's unique commercial success from the overall "overheated" or "oversold" biotech sector.
RSI 14 for the overall market
Tarsus Pharmaceuticals (TARS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TARS (Tarsus Pharmaceuticals)
Tarsus Pharmaceuticals is a biopharmaceutical company focused on ophthalmology. Its first commercial product, Xdemvy, is designed to treat demodectic blepharitis (inflammation of the eyelids). This chart shows the average price target from analysts, reflecting their expectations for the launch of this new drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TARS-Tarsus-Pharmaceuticals&v=1772617283355 "A chart showing analyst consensus forecasts for the expected stock price. TARS (Tarsus Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price TARS (Tarsus Pharmaceuticals)
Tarsus Pharmaceuticals (TARS) is a biopharmaceutical company whose first product (XDEMVY) was a breakthrough in the treatment of demodectic blepharitis (an eyelid inflammation caused by mites). This chart shows their commercialization estimate. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their first drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TARS-Tarsus-Pharmaceuticals&v=1772617283358 "A chart showing the difference between the consensus forecast and the actual stock price. TARS (Tarsus Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Tarsus Pharmaceuticals is a biopharmaceutical company whose flagship product is Xdemvy, the first eye drops for the treatment of demodectic blepharitis (eyelid inflammation caused by the mite). This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe a new niche will emerge in the ophthalmology market.
Analysts' consensus forecast for the overall market share price
Tarsus Pharmaceuticals (TARS) is a biotech company focused on niche eye diseases (e.g., Demodex blepharitis). This chart of overall market sentiment is important. Optimism = the market is willing to fund R&D. However, TARS already has a product, so during a recession (pessimism), investors may appreciate the non-cyclical nature of treatment demand.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biotech company focused on ophthalmology. Their first commercial product (Xdemvy) is a breakthrough and the only treatment for demodectic blepharitis (an eyelid inflammation caused by mites). This chart is an assessment of their commercial launch, measuring how quickly doctors and patients adopt their new, previously unavailable drug.
AKIMA Market Segment Index - Pharma infections
Tarsus Pharmaceuticals (TARS) is a single-product biotech (for now); the company made a breakthrough by creating the first (and only) approved drug (Xdemvy) for Demodectic blepharitis (eyelash mites). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does Tarsus' niche monopoly (in its own disease) differentiate it from the average pharma company?
The AKIM Index for the overall market
Tarsus is a biopharmaceutical company commercializing a treatment for eyelid disease (demodectic blepharitis). Its product is Xdemvy. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this new drug launch in the "protective" sector compares to the overall economic trends affecting the markets.
